Reference Pricing: An Effective Model for the U.S. Pharmaceutical Industry? by Salter, Marie




Reference Pricing: An Effective Model for the U.S.
Pharmaceutical Industry?
Marie Salter
Follow this and additional works at: http://scholarlycommons.law.northwestern.edu/njilb
This Article is brought to you for free and open access by Northwestern University School of Law Scholarly Commons. It has been accepted for
inclusion in Northwestern Journal of International Law & Business by an authorized administrator of Northwestern University School of Law Scholarly
Commons.
Recommended Citation
Marie Salter, Reference Pricing: An Effective Model for the U.S. Pharmaceutical Industry?, 35 Nw. J. Int'l L. & Bus. 413 (2015).
http://scholarlycommons.law.northwestern.edu/njilb/vol35/iss2/5
5SALTER.DOCX (DO NOT DELETE)  9/29/15 1:56 PM 
 
Copyright 2015 by Northwestern University School of Law Printed in U.S.A. 
Northwestern Journal of International Law & Business Vol. 35, No. 2 
413 
 
Reference Pricing: An Effective Model for the U.S. 
Pharmaceutical Industry? 
 
By Marie Salter* 
Abstract: The pharmaceutical industry stands at a peculiar place in the United 
States. It is one of the largest industries in the United States, “enjoy[ing] profit 
margins nearly four times that of the average Fortune 500 company.” It is also 
a global leader, responsible for an enormous amount of research and 
development. Despite its size and power, the U.S. pharmaceutical industry is 
largely reviled, Perhaps what differentiates the U.S. pharmaceutical industry 
from the pharmaceutical industries of other nations is its “free market” price 
setting. Other nations, particularly those in the European Union, use 
government price controls to keep pharmaceutical prices low. One of the most 
popular systems of price control is reference pricing. Reference pricing is a 
method of controlling spending on drug reimbursement by using the price of 
similar or existing drugs to set “a reimbursement tariff (called reference price) 
for groups of drugs which are considered to be ‘interchangeable.’” This 
Comment explores the validity of reference pricing as a method of reducing 
government healthcare spending, particularly in the United States, through 
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The pharmaceutical industry stands at a peculiar place in the United 
States. It is one of the largest industries in the United States, “enjoy[ing] 
profit margins nearly four times that of the average Fortune 500 company.”1 
It is also a global leader, responsible for an enormous amount of research 
and development. Despite its size and power, the U.S. pharmaceutical 
industry is largely reviled. “Big Pharma” casts a shadow over national 
dialogue—both the formal public dialogue through the media and the more 
informal dialogue which takes place across the internet.2 Perhaps what 
differentiates the U.S. pharmaceutical industry from the pharmaceutical 
industries of other nations is its “free market” price setting. Other nations, 
particularly those in the European Union, use government price controls to 
keep pharmaceutical prices low. One of the most popular systems of price 
control is reference pricing. Reference pricing is a method of controlling 
spending on drug reimbursement by using the price of similar or existing 
drugs to set “a reimbursement tariff (called reference price) for groups of 
drugs which are considered to be ‘interchangeable.’”3 
This Comment explores the validity of reference pricing as a method 
of reducing government healthcare spending, particularly in the United 
States, through comparison to foreign price controls. Part II discusses the 
features of reference pricing and describes the various forms that reference 
pricing takes within the European Union. Part III focuses on Germany and 
its unique place in the European Union as a reference country, while Part IV 
analyzes reference pricing as it is used in France. Finally, Part V discusses 
the current state of healthcare and pharmaceutical industries in the United 
States and argues that a system of reference pricing will be effective in the 







 1 Jerry Stanton, Comment, Lesson for the United States From Foreign Price Controls on 
Pharmaceuticals, 16 CONN. J. INT’L L. 149, 154 (2000). 
 2 A Google search for the much-touted phrase “big pharma” reveals a variety of sites of questionable 
veracity, including everything from “mommy bloggers,” to a natural lifestyle website, to mass market 
books like the following: JACKY LAW, BIG PHARMA: HOW THE WORLD’S BIGGEST DRUG COMPANIES 
CONTROL ILLNESSES (2006). 
 3 CHRISTINE HUTTIN, Experiences with Reference Pricing, in DRUGS AND MONEY — PRICES, 
AFFORDABILITY, AND COST CONTAINMENT 85 (C.P. de Joncheere et al. eds., 7th ed. 2003), available at 
http://apps.who.int/medicinedocs/pdf/s4912e/s4912e.pdfhttp://apps.who.int/medicinedocs/ 
en/d/Js4912e/3.3.html#Js4912e.3.3. 
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II. REFERENCE PRICING DEFINED 
 
Many countries use reference pricing as a method for pricing 
pharmaceuticals for government reimbursement.4 Reference pricing is 
usually enacted through a healthcare reform law, and then put into action 
through specially created government committees or already existing public 
health committees.5 Under reference pricing, interchangeable medicines6 
are divided into groups.7 The prices of these drugs are then compared to the 
prices for the same drugs in select international markets and set 
accordingly.8 Which countries are used for comparison is either specified in 
the originating law or determined by a government agency.9 
After reference prices are set, if a pharmaceutical company continues 
to price their medication beyond the reference point, the consumer must pay 
the additional cost beyond the reference price.10 Typically, neither a 
consumer’s insurance nor the government payor system pays the difference, 
though some private insurance plans or “luxury” additional insurance plans 
do cover higher cost drugs.11 These systems are utilized in virtually every 
developed nation outside of the United States.12 
Though some countries utilize reference pricing as an informal 
benchmark, many have codified reference pricing in their regulatory 
 
 4 Lana Kraus, Note, Medication Misadventures: The Interaction of International Reference Pricing 
and Parallel Trade in the Pharmaceutical Industry, 37 VAND. J. TRANSNAT’L L. 527, 529 (2004). The 
terms “reference pricing” and “international reference pricing” are used interchangeably throughout this 
Note—merely reflecting the U.S.-based perspective of the analysis—because the United States does not 
currently use a system of reference pricing. 
 5 Reference Prices and How They Are Set, GEMEINSAMER BUNDESAUSSCHUSS (Feb. 9, 2014), 
http://www.english.g-ba.de/special-topics/pharmaceuticals/reference/; Kraus, supra note 4, at 536. 
 6 Interchangeable medicines are typically biosimilars or bioequivalents. For an explanation of how 
these are defined, see subpart II(A). 
 7 Pieter Dylst et al., Reference Pricing Systems in Europe: Characteristics and Consequences, 1 
GABI J. 127, 128 (2012). 
 8 The exact calculations in arriving at this number depend on what a given government chooses to 
base their reference pricing on. Some calculation systems, which will be discussed hereinafter, include 
but are not limited to the following: average price of medicines, average price of generic medicines, 
lowest-priced generic, and more complex systems which balance weighted averages or take into account 
a larger number of low-priced generics. See Dylst, supra note 7. 
 9 For a more detailed discussion of how these countries are chosen, see subpart II(A). 
 10  See Lisa Brandt, Price Tagging the Priceless: International Reference Pricing for Medicines in 
Theory and Practice, EUROPEAN CENTRE FOR INTERNATIONAL POLITICAL ECONOMY, at 2 (2013), 
available at http://www.ecipe.org/app/uploads/2014/12/ECIPE_Policy_Brief_IRP_30_May_FINAL_ 
pdf.pdf; PHARMACEUTICAL BENEFITS BOARD, THE SWEDISH PHARMACEUTICAL REIMBURSEMENT 
SYSTEM - A BRIEF OVERVIEW 8 (2007) [hereinafter TLV], available at http://www.tlv.se/Upload/ 
English/ENG-swe-pharma-reimbursement-system.pdf. 
 11  See sources cited supra note 10. 
 12  Brandt, supra note 10; Stanton, supra note 1. 
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systems.13 However, these systems are not regulated by any international 
body. Instead, international reference pricing is governed and defined by 
each country that elects to utilize such a system. In general, countries which 
institute reference-pricing systems have some semblance of “socialized 
medicine.”14 Additionally, almost all reference-pricing countries base their 
pricing models largely on countries with low pharmaceutical prices.15 
However, because there is no governing body managing the prices 
governments set for pharmaceuticals, each government utilizing reference 
pricing has a great deal of discretion in setting prices and negotiating with 
pharmaceutical companies. This can result in a large disparity in 
pharmaceutical prices between different countries, at times seemingly at 
odds with the per capita income of these countries, leading to poorer 
countries paying high prices for pharmaceuticals.16 
 
A. How Reference Groups are Defined 
 
Reference groups are established based on three basic identifiers either 
alone or in combination. These identifiers are the following: active 
substance or ingredient, pharmacological class, and therapeutic class. 
Active ingredient is defined by the World Health Organization (WHO) 
as “‘[a]ny substance or combination of substances used in a finished 
pharmaceutical product (FPP), intended to furnish pharmacological activity 
or to otherwise have direct effect in the diagnosis, cure, mitigation, 
treatment or prevention of disease, or to have direct effect in restoring, 
correcting or modifying physiological functions in human beings.’”17 
 
 13  See generally U.S. DEP’T OF COMMERCE, INT’L TRADE ADMIN., PHARMACEUTICAL PRICE 
CONTROLS IN OECD COUNTRIES IMPLICATIONS FOR U.S. CONSUMERS, PRICING, RESEARCH AND 
DEVELOPMENT, AND INNOVATION [hereinafter ITA], available at http://www.ita.doc.gov/td/ 
chemicals/drugpricingstudy.pdf. 
 14  Socialized medicine, however, is generally a term only used by the U.S. media. 
 15  Although they are not included in this comparison, this particular feature of International 
Reference Pricing may have an extremely detrimental effect on developing nations. Drug developers 
have historically offered lower-price drugs to developing nations, particularly in instances of outbreak or 
pervasive disease, as well as diseases which develop due to lack of clean food and water which are 
common in developing nations. When developed nations craft reference prices, they often bundle these 
lower-priced drugs into their averages. As a result, drug developers’ profits suffer because the 
reimbursement price is lowered in developed nations, which make up the majority of their profit 
margins. Perhaps as a result of this, drug companies have displayed reluctance to provide low-cost drugs 
to developing nations. See Patricia Danzon & Adrian Towse, Differential Pricing for Pharmaceuticals: 
Reconciling Access, R&D and Patents, 3 INT’L J. HEALTH CARE FIN. & ECON. 183, 185 (2003). 
 16  These differences are often held as the reason behind the thriving black or grey markets in 
international pharmaceuticals, notably, between the United States and Canada. See Paula Tironi, Article, 
Pharmaceutical Pricing: A Review of Proposals to Improve Access and Affordability of Prescription 
Drugs, 19 ANNALS HEALTH L. 311, 351 (2010). 
 17  World Health Organization, Definition of Active Pharmaceutical Ingredient (World Health Org., 
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Generic drugs are bioequivalents of name brand drugs, meaning that the 
active ingredient is functionally or literally the same and is delivered in a 
similar dosage. Beyond these active ingredients, generics can differ in their 
fillers, colorants, binding agents, and other elements.18 
Reference groupings based on active ingredient does not take such 
nonactive differences between generic and name brand drugs into account 
while creating medication groups. Such a system may encourage the 
manufacture of biosimilars, or medications which have a similar therapeutic 
effect but are based on a different active ingredient. These medications 
would be classified in different reference groups and would be priced 
differently.19 A biosimilar without a generic substitute, for example, would 
fare well in a system which allowed it to be priced independently of a 
medicine with a similar effect but many generic versions.20 Countries which 
define reference groups based on active ingredient include Belgium, 
Finland, France, and Hungary.21 This method is the most popular method of 
defining reference groups.22 
Another method of crafting reference groups is by pharmacological 
class. “[A] pharmacologic class is a group of drugs that share scientifically 
documented properties.”23 These documented properties might include the 
mechanism of action (the effect of the drug “at the receptor, membrane, or 
tissue level”), physiologic effect “at the organ, system, or whole body 
level,” or the chemical structure of the drug.24 In the United States, the Food 
 
Working Document QAS/11.426/Rev.1, 2011), available at http://www.who.int/medicines/areas/ 
quality_safety/quality_ assurance/DefinitionAPI-QAS11-426Rev1-08082011.pdf. 
 18  See Colleen Kelly, The Balance Between Innovation and Competition: The Hatch-Waxman Act, 
the 2003 Amendments, and Beyond, 66 FOOD DRUG L.J. 417 (2011); Adam R. Young, Note, Generic 
Pharmaceutical Regulation in the United States with Comparison to Europe: Innovation and 
Competition, 8 WASH. U. GLOBAL STUD. L. REV. 165 (2009). 
 19  See Kraus, supra note 4. 
 20  This is similar to a common occurrence in the United States where pharmaceutical companies 
fight to maintain a market share upon the expiration of their patent. Pharmaceutical companies will often 
develop a similar product that is functionally altered enough to warrant a new patent—for example, an 
extended-release version of a medicine which has the same overall effect. These incremental changes 
are used to “evergreen” the company’s patent protection. When patients are prescribed this new version 
of the medication, a generic version does not exist to be substituted. See generally Steven Johnson, 
Innovation: It Isn’t a Matter of Left or Right, N.Y. TIMES (Oct. 30, 2010), 
http://www.nytimes.com/2010/10/31/business/31every.html?pagewanted=all; Jonathan Cohn, Creative 
Destruction, NEW REPUBLIC (Nov. 12, 2007), http://www.newrepublic.com/article/politics/creative-
destruction. 
 21  Dylst et al., supra note 7. 
 22  Id. 
 23  U.S. DEP’T OF HEALTH AND HUMAN SERV. ET AL., GUIDANCE FOR INDUSTRY AND REVIEW STAFF 
LABELING FOR HUMAN PRESCRIPTION DRUG AND BIOLOGICAL PRODUCTS — DETERMINING 
ESTABLISHED PHARMACOLOGIC CLASS FOR USE IN THE HIGHLIGHTS OF PRESCRIBING INFORMATION, at 
3 (Oct. 2009). 
 24  Id. 
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and Drug Administration (FDA) has established pharmacological classes 
based on these factors. Upon development, drugs can be classified into an 
existing pharmacological class if they fit within the criteria. The FDA has 
also established a practice for establishing new pharmacologic classes 
(though pharmacological classes are not then used for reference pricing in 
the United States).25 Developed foreign nations have enacted similar 
government processes.26 Pharmacologic classification, as well as 
therapeutic class—the classification of a drug based on the condition or 
disease it treats, rather than the more specific biological effect encompassed 
under pharmacologic class27—can lead to a wider variety of medications 
being contained within a certain reference price group. Grouping by 
pharmacologic or therapeutic class can be a more effective price control 
because it allows the price regulations to contain a larger span of 
medications within a single price group. However, grouping by 
pharmacologic or therapeutic class may also lead to undesirable patient 
outcomes as doctors are incentivized to choose medicines based on 
financial reasons rather than medical reasons.28 
 
B. How Reference Prices are Crafted 
 
Once drug classes are determined, individual drugs’ reference prices 
are generally calculated “as a function of market prices of medicines.”29 
However, which medicines that are taken into account in considering the 
market price varies widely among different countries within and outside of 
the European Union. Croatia and Hungary, for example, set reference prices 
based on the average price of all medicines within a group. Other methods 
include setting prices by the lowest price in a group, pricing based on the 
generic drug market, and pricing by lowest price overall. 
By far, the most popular method is to set the reference price for a 
designated group of drugs—often separated by class—based on other 
countries’ lowest priced medicines within that designated group’s reference 
points. Bulgaria, the Czech Republic, Finland, Italy, Poland, Spain, and 
Turkey use this method alone or in addition to other methods.30 While 
 
 25  Id. at 6. 
 26  See generally Drummond et al., Reimbursement of Pharmaceuticals: Reference Pricing Versus 
Health Technology Assessment, 12 EUR. J. HEALTH ECON. 263 (2011); Kraus, supra note 4. 
 27  Kraus, supra note 4. The difference between pharmacologic and therapeutic classification is subtle 
but important. Pharmacological class is grouped solely by the drug’s effects on the body, while 
therapeutic class focuses on the particular disease or condition the drug is intended to treat. These 
groups often overlap, but can also diverge strongly. 
 28  Danzon, supra note 15; Stephen A. Talmadge, Influencing Physicians’ Prescribing Behavior: 
Ethical Issues Related to Pharmaceutical Gifts, 11 MICH. ST. U. J. MED. & L. 303, 311 (2008). 
 29  Talmadge, supra note 28. 
 30  Id. 
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lower priced medicines often include generic medicines simply because 
generic medications are priced on a different scale by companies (which 
usually do not need to account for research and development in pricing 
generics), this method does not focus specifically on generic medicines in 
assigning prices and often includes competitively priced name brand 
drugs.31 
Pricing by lowest price overall, however, may undermine the 
development of generic drug markets in countries where lowest price is 
used without special attention to generics. The generic market depends on 
competitive prices to sustain itself because generic manufacturers are not, 
for the most part, companies that also develop new drugs for the market. A 
system based on lowest price urges developers of name brand drugs to 
compete on price with generics because they can no longer be guaranteed a 
premium for their product.32 This is undesirable to originators as well 
because they spend millions on research and development and rely on 
higher prices to recoup these costs. 
Some nations, which place more importance on a national market for 
generic medicines, have based their reference prices directly on generic 
medicines alone. In France, reference prices are set by looking to the 
average price of generic medicines within a designated group or class in 
chosen reference countries, while Denmark and Latvia use a similar system 
based on the lowest priced generic medicine.33 Countries which base 
reference prices on generics generally intend reference pricing to serve in 
part as a mechanism to grow the market of generic pharmaceuticals. 
Continuing decreases in price are obviously a positive result for 
government payors and consumers in terms of cost, but can result in a 
pricing “race to the bottom” that places insurmountable strain on 
pharmaceutical manufacturers.34 
 
C. Effect of Reference Pricing on Foreign Governments and  
 Pharmaceutical Companies 
 
Foreign governments, particularly in the European Union, are 
increasingly looking to regulate healthcare across the board. As populations 
age, medical treatments become more sophisticated and healthcare costs 
rise. Reference pricing is an effective way for government payors to limit 
what they spend on pharmaceuticals. In the United States, a country which 
 
 31  For a discussion of generic pricing models, see Generic Drugs Don’t Necessarily Mean Low 
Prices, PBS NEWS HOUR, (Nov. 2, 2013, 12:00 AM), http://www.pbs.org/newshour/bb/health/july-
dec13/costlygenrics_11-02.html. 
 32  Young, supra note 18, at 183. 
 33  Id. at 182 n.98. 
 34  Id. 
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allows pharmaceutical companies near unbridled discretion in setting 
prices, the government spends approximately 8%–10% of its total health 
care costs on pharmaceuticals.35 In most other countries, reference pricing 
has been an effective method of cost saving and could be equally effective 
in the United States. 
Poland, for example, had a remarkably underfunded and inefficient 
healthcare system in the past, spending 0.63% of its Gross Domestic 
Product (GDP) on pharmaceutical reimbursements and 7% on health care 
overall. At the same time, Poland’s medical industry delivered a poor level 
of care (for example, Poland demonstrated the lowest level of access to 
cancer treatment in the EU).36 However, in 2012, Poland implemented 
health care reforms which, among other improvements, refined the system 
of reference pricing and applied more stringent caps on pharmaceutical 
reimbursements. In the same year, Poland saw, for the first time, a decrease 
in prescription reimbursement costs.37 This decrease in costs did not further 
reduce quality of care, and Poland has since realized steady improvements 
in quality of care.38 
Canada has also experienced great success through reference pricing. 
In the early 1990s, Canada began reforming their drug patent and pricing 
system in response to the North American Free Trade Agreement 
(NAFTA).39 Canada established the Patented Medicines Price Review 
Board (PMPRB), which compares drug prices in Canada to foreign prices 
for the same drug or a similar compound. For innovative medicines, prices 
are compared to nine other countries. For similar compounds (generics), 
prices are set closely to preexisting drugs internally. Since the creation of 
the PMPRB, drug prices have been consistently below the Canadian 
consumer price index.40 
Other countries, however, have used reference pricing as a method of 
controlling pharmaceutical spending in the past and subsequently 
abandoned it. Between 1993 and 2003, Sweden used a form of international 
 
 35  Stanton, supra note 1. 
 36  Joanna Lis, President of Polish Int’l Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) Chapter, Address at ISPOR 18th Annual Meeting: Pricing of Pharmaceuticals in Emerging 
Countries of the Central & Eastern European Region: The Case of POLAND 2 (May 21, 2013), 
available at http://www.ispor.org/meetings/neworleans0513/releasedpresentations/FORUM-2-Central_ 
Eastern_Europe_Lis.pdf. 
 37  Id. 
 38  Id.  
 39  This reform was largely because Canada’s patent protections included compulsory licensing 
provisions that did not conform to NAFTA. NAFTA eliminated all compulsory licensing with a few 
exceptions. In anticipation of this change, Canada passed a law commonly known as C-91, which 
updated their patent laws to conform with NAFTA. Though controversial, C-91 was renewed in 1997. 
Stanton, supra note 1, at 160. 
 40  Stanton, supra note 1, at 161. 
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reference pricing based on chemical equivalency and active ingredients.41 In 
2003, however, Sweden replaced this system with a drug substitution 
scheme. The Swedish Pharmaceutical Benefits Board cited three reasons for 
the change. First, the cost of reimbursed drugs was increasing. Second, 
Sweden’s reimbursement system was overly generous. Finally, the Board 
was concerned about value received for spending.42 Under the drug 
substation scheme system, pharmacies select the appropriate lowest priced 
drug.43 Sweden now uses a government board, the Dental and 
Pharmaceutical Benefits Agency (TLV), to decide on reimbursement levels 
for new drugs. The TLV does not use reference pricing to establish 
reimbursement levels. Rather, it uses a product-oriented system44 that 
allows for more flexibility than strict reference pricing in reimbursement 
and a generic substitution scheme similar to that used by insurance policies 
in the United States.45 Generic substitution is mandatory in Sweden. If a 
patient chooses to reject a generic drug, they must pay the difference for the 
name brand.46 
Reference pricing has an impact beyond the particular country 
imposing regulations because of the relatively small market share of foreign 
pharmaceutical companies in comparison to powerhouse pharmaceutical 
companies within the United States. In 2012, pharmaceutical research and 
development expenditures in the United States topped $36,810 million, 
while all European countries combined spent an estimated €30,000 million 
(roughly $40.5 million). Similarly, European countries developed fifty-five 
new chemical or biological entities from 2008 to 2012, while the United 
States developed sixty-five (Japan, a distant third, produced twenty-six, 
while all other nations produced sixteen).47 Still, any analyses of price 
impacts on pharmaceutical companies must take into account both foreign 
and U.S. developers who distribute to foreign markets. 
 
 41  Drummond, supra note 26. 
 42  TLV, supra note 10, at 2. 
 43  Many states in the United States have adopted a similar system through generic substitution laws. 
Jesse C. Vivian, Generic-Substitution Laws, 33 U.S. PHARM. (GENERIC DRUG REVIEW) 30 (2008). 
 44  TLV clarifies that a product-oriented system means “that medicines are either granted 
reimbursement status for the whole of its approved area of use or not at all.” TLV, supra note 10, at 4. 
 45  Danzon, supra note 15, at 13. 
 46  TLV, supra note 10, at 4. 
 47  This number represents a gradual change from decades past. From 1993 to 1997, Europe led 
development with ninety new chemical and biological entities compared to the United States’ sixty-six 
and Japan’s sixty. Europe’s numbers gradually decreased and were eclipsed by the United States from 
1998 to 2002. These numbers have improved since 2007, but still demonstrate a disparity in production, 
especially in light of the fact that Europe is considered as a whole, while the United States represents a 
single country. ECORYS RESEARCH AND CONSULTING, COMPETITIVENESS OF THE EU MARKET AND 
INDUSTRY FOR PHARMACEUTICALS — VOLUME I: WELFARE IMPLICATIONS OF REGULATION (2009), 
available at http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/vol_1_welfare_implications_ 
of_regulation_en.pdf. 
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Regardless of the production disparity between the United States and 
Europe, European pharmaceutical companies expressed concern as a 
growing number of governments began regulating pharmaceutical pricing. 
Industry members feared “the growing practice by government health 
agencies to agree or set medicine prices by reference to other countries’ 
prices,” and predicted that the lowest-common-denominator principle 
would result in an overall lowering of profit margins throughout the 
industry.48 These fears were perhaps justified, if not at the disastrous level 
indicated. In 2003, a study of Organization for Economic Cooperation and 
Development (OECD) countries based on U.S. Department of Commerce 
calculations compared estimated revenues for a group of patented drugs 
based on unregulated markets with actual profits from this set of drugs in 
various countries with extensive price regulations.49 Among the countries 
studied were France, Germany, Switzerland, and the UK.50 Each of these 
counties uses price controls of some sort, with Germany and France giving 
the most weight to reference prices within their pricing methodologies. In 
France, estimated revenues for reference-priced patented drugs were $5.3 
billion,51 while actual revenues were $3.8 billion. Similarly, estimated 
revenues in Germany were $4.7 billion, while actual revenues were $3.5 
billion.52 
These revenue differences and the anticipation of falling revenues can 
have a direct effect on the behavior of pharmaceutical companies in four 
ways. First, it may influence where companies initially choose to release 
and market drugs.53 It is in a pharmaceutical company’s best interest to 
originate a drug in a country where they are free to set the price according 
to their own pricing models—allowing them to potentially recoup research 
and development costs that are not taken into account when setting 
reference prices. Understandably, these countries might be less receptive to 
high prices if a drug has already launched at a lower price in other 
countries.54 
Second, companies will attempt to ensure higher prices in other 
countries through gaming reference lists. Originating drugs in countries 
 
 48  Pharma “is Losing Control of Pricing, and Must Present a United Case Now:” KPMG, 
PHARMALETTER (June 17, 2002) [hereinafter Pharmaletter], available at 
http://www.thepharmaletter.com/article/pharma-is-losing-control-of-pricing-and-must-present-a-united-
case-now-kpmg. 
 49  See ITA, supra note 13, at fig. 5. 
 50  See id. 
 51  Using U.S. Dollars as the standard currency unit. 
 52  ITA, supra note 13, at fig. 5. 
 53 Drummond et al., supra note 26. 
 54  Peter J. Rankin et al., Global Pricing Strategies for Pharmaceutical Product Launches, in THE 
PHARMACEUTICAL PRICING COMPENDIUM 5 (2003), available at http://www.crai.com/sites/default/ 
files/publications/Global-Pricing-Strategies-for-Pharmaceutical-Product-Launches.pdf. 
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without pricing regulations creates a higher reference point for pricing when 
the drug is launched in countries that consider the “first-launch” country as 
a reference point in their analysis.55 While countries generally seek lower 
priced reference points rather than highly priced, first-launch prices, 
pharmaceutical companies working in referenced-priced systems attempt to 
force pricing lists as high as possible.56 
Third, beyond the ability to set their own prices, pharmaceutical 
companies give preference to countries that allow them to negotiate a 
pricing and reimbursement scheme before marketing authorization is 
granted, which allows them to gain a clearer picture of the gains of the 
marketplace before taking substantive steps towards launching the drug.57 
Finally, reference-pricing systems may also have an effect on research 
and development in European markets because these costs are less likely to 
be recouped. According to a 2009 study by independent consultants 
analyzing the European pharmaceutical market, price regulations “will 
lower a firm’s expected returns to R&D and reduce the demand for R&D 
investments.”58 However, this is not based on direct numbers, but on a 
projection study based on research and development in the United States.59 
While the potential effect of reference pricing on research and development 
in the U.S. pharmaceutical industry will be discussed in Part IV, it is 
difficult to assign reference pricing as causation rather than correlation in 
relation to European research and development decreases. 
 
III. FRANCE & GERMANY 
 
Germany, a major pharmaceutical market in the European Union, does 
not use a strict reference pricing system. However, Germany was one of the 
first countries to utilize reference pricing and was often looked to by other 
countries in setting their pharmaceutical prices.60 Because of this, price 
changes in Germany have the potential to create wide ripple effects beyond 
Germany itself. 
Germany requires health coverage for all citizens. In turn, 90% of 
 
 55  Id. 
 56  Id. at 52; Drummond et al., supra note 26. 
 57  KAI RUGGERI & ELLEN NOLTE, RAND CORP., PHARMACEUTICAL PRICING: THE USE OF 
EXTERNAL REFERENCE PRICING (2013), available at http://www.rand.org/content/dam/rand/ 
pubs/research_reports/RR200/RR240/RAND_RR240.pdf.; Patricia M. Danzon & Jonathan D. Ketcham, 
Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, The Netherlands and 
New Zealand (Nat’l Bureau of Econ. Research, Working Paper No. 10007, 2004); Dylst et al., supra 
note 7. 
 58  RUGGERI & NOLTE, supra note 57. 
 59  Id. 
 60  Danzon, supra note 15. 
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German citizens are covered by federal statutory health insurance (SHI).61 
The German healthcare system is regulated “within the Social Code Book V 
(Sozialgesetzbuch), which sets out the overall framework for the statutory 
health insurance system . . . , including coverage and reimbursement of 
medicines under the statutory system.”62 Article 78 of the Pharmaceutical 
Act, passed in 1976, regulates prescription medication safety and states that 
the Ministry of Economics and Technology must supervise the 
pharmaceutical pricing.63 
Manufacturers primarily drive German pharmaceutical prices.64 Highly 
innovative drugs in particular are not subject to reference prices, and 
manufacturers can set prices at will. However, a complex system of 
regulations and internal referencing influence reimbursement rates for SHI. 
Manufacturers are required to provide rebates to SHI funds, which differ 
depending on whether the drug in question is a patented innovative drug or 
an off-patent, generic drug.65 Additionally, hospitals may negotiate rebates 
for inpatient drugs, and manufacturers may negotiate with retailers for 
discounts or rebates.66 In short, the German pharmaceutical market is more 
regulated than it appears on its face. 
In 2007, Germany instituted healthcare reform.67 In November 2010, 
the Act on the Reform of the Market for Medicinal Products (ANM) was 
passed which stipulated that “from 2011 all newly licensed medicines are 
subject to a (‘early’) benefit assessment; this assessment forms the basis for 
determining the price of the new product.”68 Manufacturers must submit a 
dossier to the Federal Joint Committee supporting the benefit of the drug, 
and indicating that the drug is recently licensed for use or for a new 
therapeutic indication. The Committee then releases a report describing, 
among other things, “requirements for appropriate use and costs.”69 The 
report is used as the basis for pricing the product. 
France, another country which utilizes price limits, uses various factors 
to set price limits, including reference prices. France also considers 
therapeutic merit and the economic contribution of the drug.70 Beyond these 
overarching factors, France looks at particular drugs to consider what 
proportion of the overall national drug expenditure they make up. If a 
 
 61  Id. at 41. 
 62  Id. 
 63  Id.; Dylst et al., supra note 7. 
 64  RUGGERI & NOLTE, supra note 57, at 41. 
 65  Id. at 42. 
 66  Id. 
 67  Id.; Dylst et al., supra note 7. 
 68  RUGGERI & NOLTE, supra note 57, at 43. 
 69  Id. 
 70  Id. at 39. 
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particular drug is a large portion of national expenditures, a cap is applied 
on what the government will pay for that particular drug.71 This system of 
capping frequently prescribed drugs may be very useful in the United 
States. In particular, this would be useful in relation to drugs that treat 
diseases that are growing more common in the United States, such as 
diabetes and other obesity related illnesses. 
 
IV. REFERENCE PRICING WOULD BE AN EFFECTIVE SYSTEM 
IN THE U.S.  
 
International Reference pricing is increasingly common and has 
proven effective in foreign markets, especially in Europe.72 However, it is 
not currently used in the U.S. Now, as U.S. healthcare reform is a popular 
topic, the opportunity exists to bundle pharmaceutical pricing reform into 
other healthcare reforms just as other countries have introduced reference 
pricing through healthcare reform.73 Part IV considers the application of 
reference pricing to the U.S. pharmaceutical market. Subpart A describes 
the current system of pricing in the U.S. and the restrictions placed on the 
pharmaceutical industry, particularly through patent law. It also describes 
regulated pricing already in effect—Medicare, Medicaid, and specialized 
pricing for veteran services. Subpart B considers the impact of a pricing 
change on the pharmaceutical industry, while subpart C analyzes the 
potential effects such a change could have on patients and providers. 
Subpart D looks to the recently enacted Affordable Care Act and how a 
reference-pricing system would be affected by the Act. 
 
A. The Current State of Pharmaceutical Pricing in the United States 
 
The United States is the only developed nation that does not use some 
sort of government regulation to control pharmaceutical pricing.74 The U.S. 
government, like other developed nations, regulates the health and safety of 
its citizens.75 Part of this regulation includes the distribution and 
manufacture of pharmaceuticals,76 much of which is executed under the 
Federal Food, Drug, and Cosmetic Act (FFDCA).77 Under the FFDCA, the 
government interacts directly with pharmaceutical manufacturers by 
collecting fees and regulating the process of releasing drugs to the market, 
 
 71  Stanton, supra note 1, at 162. 
 72  See generally Huttin, supra note 3; Stanton, supra note 1; Dylst et al., supra note 7. 
 73  For examples, see generally Stanton, supra note 1. 
 74  See generally Kraus, supra note 4. 
 75  See Young, supra note 18, at 169–71. 
 76  Id. 
 77  Id. at 168. 
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as well as evaluating the safety of those drugs for consumers.78 Through the 
FFDCA, manufacturers must complete and file “new drug applications.” 
These applications must include extensive reports detailing “the safety and 
effectiveness of the drug; a full statement of the composition of the drug; a 
full description of the methods, facilities, and controls used at all levels of 
production; samples of the drug; and specimens of the labeling that may be 
used for the drug.”79 
Despite these regulations, the United States differs from other 
developed nations in that manufacturers usually set pharmaceutical pricing. 
Pharmaceutical innovators—manufacturers that research and develop new 
drugs—obtain FDA approval and patent protection as the drug moves 
through several testing phases.80 At this point, patent protection allows 
originators to charge monopoly prices for the duration of the patent.81 
Companies balance a variety of factors to set drug prices. The most obvious 
of these is research and development expenditure because companies seek 
to recoup their investment. However, since drug prices are largely inelastic 
(increasing the price does not decrease the demand), companies also take 
into account how much insurers and patients will value the drug, the current 
marketplace, and a variety of other factors.82 
Nevertheless, some price-control mechanisms do exist. Such 
mechanisms include government actions which affect the entire 
pharmaceutical industry, like the Hatch–Waxman Act, a bill which 
encourages generic production by expediting the process of generic drug 
approval.83 However, the United States has also engaged in more limited 
price setting through programs like Medicare, Medicaid, and the 
Department of Veterans Affairs insurance plans. These smaller price 
controls more closely resemble the price controls used in other developed 
nations, and use reference pricing in various ways to create price limits. 
 
1. The Hatch–Waxman Act 
 
Traditionally, the U.S. patent system has protected drug originators 
 
 78  Id. 
 79  Vaishali V. Shah, Note, Prescription Drugs in America: The Pain of Pricing has an Unpromising 
Cure, 2006 U. ILL. L. REV 859, 861 (2006). 
 80  Seth D. Knocke, Incentivizing Innovation: Pharmaceutical Pricing in the United States and the 
United Kingdom, 20 ANNALS HEALTH L. ADVANCE DIRECTIVE 177, 179 (2011). 
 81  Tironi, supra note 16, at 323. 
 82  See Barry Werth, A Tale of Two Drugs, MIT TECH. REV. (Oct. 22, 2013), 
http://www.technologyreview.com/featuredstory/520441/a-tale-of-two-drugs/ (describing French drug 
maker Sanofi’s fatal misstep in overpricing drug Zaltrap when a near equivalent drug already existed at 
a much lower price). 
 83  See, e.g., D. Christopher Ohly & Sailesh K. Patel, The Hatch-Waxman Act: Prescriptions for 
Innovative and Inexpensive Medicines, 19 U. BALT. INTELL. PROP. L.J. 107 (2011). 
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from losing a large market share to bioequivalent competitors who release 
equivalent drugs and capture market share by offering lower prices.84 The 
U.S. patent system originates from Article 1 of the Constitution, which 
states that Congress shall have the power “to promote the progress of 
science and the useful arts, by securing for limited times to authors and 
inventors the exclusive right to their respective writings and discoveries.”85 
Patent protections encourage development by providing companies the 
opportunity to potentially recoup the costs of research and development if 
they are given market control for the lifespan of their patent.86 
However, extensive use of these patent controls also elicits criticism. 
Strict patent controls create drug monopolies that theoretically allow 
developers to raise prices indiscriminately as high as the market will 
allow.87 These drug monopolies can have extremely detrimental effects on 
patient outcomes, as patients avoid taking medications or take smaller doses 
to save money on prescriptions.88 Additionally, generic-drug companies 
were required to complete the same FFDCA process to gain approval as 
innovators, an expensive and time-consuming process.89 Rather than using 
the trial results and research completed by originators, generic 
manufacturers were required to conduct the same tests and repeat research, 
despite utilizing equivalent ingredients which would virtually guarantee the 
same results. Many generic manufacturers were unable to shoulder the 
development costs involved in gaining approval through the FFDCA 
process or maintained prices close to the originator drug to afford the costs 
of FFDCA approval.90 Because generic manufacturers were saddled with 
these costs and unable to significantly lower prices, consumers did not 
benefit fully from the presence of generics in the market. 
In 1984, the Drug Price Competition and Patent Term Restoration Act, 
known as the Hatch–Waxman Act, was passed, with the goal of 
“expedit[ing] and streamlin[ing] both generic drug approvals and patent 
 
 84  Although there is some overlap, drug companies are typically divided into two categories, which 
will be referred to in this Note as originators and generic manufacturers. Originators invest in research 
and development and are rewarded with patent protection when they release a drug into the market. 
Generic manufacturers develop a bioequivalent, which is given access to the market through Hatch-
Waxman protections. Daniel J. Gifford, Government Policy towards Innovation in the United States, 
Canada, and the European Union as Manifested in Patent, Copyright, and Competition Laws, 57 SMU 
L. REV. 1339, 1342 (2004). 
 85  U.S. CONST. art. I, § 8, cl. 8. 
 86  Ohly, supra note 83. 
 87  See Werth, supra note 82. 
 88  Tironi, supra note 16, at 321 (“More than 60 percent of the uninsured chronically ill, and 46 
percent of the underinsured chronically ill report skipping medication due to cost.”). 
 89  Knocke, supra note 80. 
 90  Allen M. Sokal, The Hatch-Waxman Act: Encouraging Innovation and Generic Drug 
Competition, FINNEGAN (2010), available athttp://www.finnegan.com/resources/articles/ 
articlesdetail.aspx?news=dfef53ed-54e4-491a-802a-01becb1f47bb. 
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litigation involving generic drugs.”91 One of the major provisions of the 
Hatch–Waxman Act is a new method of applying for drug approval for 
companies that manufacture bioequivalent generics. Instead of repeating the 
same cumbersome tests, generic manufacturers can now complete a shorter, 
less rigorous application which “piggybacks” the application filed by the 
innovator.92 This allows generic manufacturers to save both time and money 
when entering the market, making the process smoother and benefitting 
both manufacturers and consumers.93 
With the advent of the Hatch–Waxman Act, the generic market in the 
United States has grown.94 However, the generic market under Hatch–
Waxman depends heavily on price advantages to maintain market share. 
Because of this, the generic-market players in the United States might resist 
reference pricing, which lowers originator prices and lessens their price 
advantage in the market. Likely, generic manufacturers would join 
originators in lobbying against this regulation. 
 
2. Medicare & Medicaid 
 
Medicare is “a government health insurance program for individuals 
age sixty-five or older, certain disabled persons, and those with kidney 
failure who require dialysis (End-Stage Renal Disease, or ERSD).”95 
Because reimbursements from Medicare come from a government agency, 
Medicare allows for closer price control than the remaining majority of the 
U.S. pharmaceutical market. 
Medicare covers “services and supplies considered medically 
necessary to treat a disease or condition.”96 Though each insurance agency 
defines “medically necessary” internally, Medicare defines it as “services or 
supplies that are needed to diagnose or treat [a] medical condition and that 
meet accepted standards of medical practice.”97 Medicare is divided into 
two sections for purposes of providing and reimbursing care and services. 
 
 91  Lisa Barons Pensabene & Dennis Gregory, Hatch-Waxman Act: Overview, PRACTICAL L. CO. 
(INTEL. PROP. & TECH.), available at http://www.fitzpatrickcella.com/DB6EDC/assets/files/ 
News/Hatch-Waxman%20Act%20Overview%20lpensabene_dgregory.pdf; Kelly, supra note 18; Ohly, 
supra note 83. 
 92  Ohly, supra note 83. 
 93  Id. 
 94  CONG. BUDGET OFF., HOW INCREASED COMPETITION FROM GENERIC DRUGS HAS AFFECTED 
PRICES AND RETURNS IN THE PHARMACEUTICAL INDUSTRY 27 (1998), available at 
http://www.cbo.gov/sites/default/files/pharm.pdf. 
 95  Tironi, supra note 16, at 330. 
 96  What does Part A cover?, MEDICARE, http://www.medicare.gov/what-medicare-covers/part-
a/what-part-a-covers.html (last visited Sept. 17, 2014.). 
 97  What does Part B cover?, MEDICARE, http://www.medicare.gov/what-medicare-covers/part-
b/what-medicare-part-b-covers.html (last visited Sept. 17, 2014). 
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Medicare Part A includes hospital care, skilled nursing care, hospice, and 
other services.98 Part A originally reimbursed pharmaceutical expenses 
directly as an itemized part of hospital costs. However, today Part A covers 
hospital expenses as a whole at a flat rate without separately charging for 
pharmaceuticals.99 If hospitals are less able to account for fluctuating prices 
of drugs, they may have to swallow the costs of drugs which are priced 
higher than the reimbursement flat rate for the hospital stay as a whole.100 
Medicare Part B, on the other hand, incorporates some of the 
principles of price control used in the European Union. Part B covers both 
medically necessary services and preventative services.101 Medically 
necessary services include “services or supplies that are needed to diagnose 
or treat your medical condition and that meet accepted standards of medical 
practice.”102 This can include ambulance services, inpatient mental health 
services, and durable medical equipment. Preventative services is defined as 
“health care to prevent illness . . . or detect it at an early stage, when 
treatment is most likely to work best.”103 
Part B covers prescription drugs on a limited basis, such as drugs that 
are disbursed in the physician’s office.104 These reimbursements have, prior 
to 2004, been made based on the Average Wholesale Price (AWP). AWP is 
the “sticker price” listed by manufacturers in a national listing of 
pharmaceuticals.105 Pharmaceuticals were reimbursed at either 95% of the 
AWP or the physician’s billing rate. In 2004, the Medicare Prescription 
Drug, Improvement, and Modernization Act (MMA) changed the pricing 
model to 106% of the Average Sale Price (ASP), “defined by statute and 
based on reports of actual transactions.”106 The ASP pricing model 
mechanism allows Medicare to reimburse at lower rates than under the 
AWP.107 Though ASP pricing is not externally influenced like reference 
pricing, it represents a level of price control that does not exist outside of 
Medicare. 
Medicaid, another form of government-run health coverage, covers 
“some low-income people, families and children, pregnant women, the 
elderly, and people with disabilities.”108 Since Medicaid is run on a state-
 
 98  What does Part A cover?, supra note 96. 
 99  Id. 
 100  Stanton, supra note 1. 
 101  What does Part B cover?, supra note 97. 
 102  Id. 
 103  Id. 
 104  Tironi, supra note 16, at 331. 
 105  As Tironi notes, “It is not an actual average of prices paid by wholesalers.” Tironi, supra note 16, 
at 331. 
 106  Id. 
 107  Id. 
 108  Medicaid & CHIP coverage, HEALTHCARE.GOV, https://www.healthcare.gov/medicaid-
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by-state basis, prescription drug coverage varies by state. However, many 
states utilize limits on prescription reimbursement, often based on AWP. 
 
3. The Office of Veterans Affairs 
 
The Veterans Health Care Act of 1992 established the 340B program, 
which “allows certain federally funded grantees and other safety net 
providers to purchase prescription drugs at reduced prices.”109 Under 340B, 
drug companies must sell to 340B entities at a reduced price, based on a 
“340B ceiling price” which “requires discounts of at least fifteen percent of 
the Average Manufacturer Price (AMP) for generics.”110 AMP (not to be 
confused with AWP) is calculated by a federally regulated formula: 
 
The manufacturer calculates pricing information for all of its 
covered outpatient drugs and sends this pricing data to HCFA 
within 30 days after the end of the quarter. HCFA will provide 
PHS with the data necessary for PHS to determine the ceiling 
price which will be used for resolving disputes, studies involving 
pricing data, auditing manufacturers, or other program 
purposes.111 
 
The 340B program covers the following outpatient drugs: FDA-
approved prescription drugs; over-the-counter (OTC) drugs written on a 
prescription; biological products that can be dispensed only by a 
prescription (other than vaccines); or FDA-approved insulin.112 
 
B. Potential Effects of Reference Pricing on the Pharmaceutical 
Industry in the United States 
 
Using international reference pricing would have widespread effects 
on the U.S. pharmaceutical industry. Some of these effects can be predicted 
by looking to other countries that use international reference pricing. 
However, the U.S. pharmaceutical industry is distinctive in its size and 
level of innovation. Because of this, the effects on the U.S. market could be 
different in terms of innovation, transformational care, black and grey 
 
chip/getting-medicaid-chip/ (last visited Sept. 8, 2014). 
 109  Tironi, supra note 16, at 334. 
 110  Id. 
 111  Notice Regarding Section 602 of the Veterans Health Care Act of 1992; New Drug Pricing, 60 
Fed. Reg. 51,488-89 (Oct. 2, 1995), available at http://www.hrsa.gov/opa/programrequirements/ 
federalregisternotices/newdrugpricing100295.pdf. 
 112  Eligibility and Registration, U.S. DEP’T OF HEALTH AND HUMAN SERVS., 
http://www.hrsa.gov/opa/eligibilityandregistration/index.html (last visited Nov. 28, 2014). 
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Among developed nations, the United States pharmaceutical market is 
unique because of its comparative lack of government price controls. In 
particular, the United States features a free market for pharmaceuticals that 
is largely unregulated by government controls like reference pricing or price 
ceilings.113 As such, pharmaceutical companies are able to charge prices in 
the United States that allow them to recoup a portion of the companies’ 
research and development costs that often go unrecouped in other 
markets.114 Patients in the United States pay more than consumers in other 
markets. For example, a 2003 study of thirty drugs found that U.S. 
consumers paid more for these drugs than consumers in the U.K. and 
France.115 
“The U.S. biopharmaceutical sector accounts for the single largest 
share of all U.S. business R&D, representing nearly 20% of all domestic 
R&D funded by U.S. businesses.”116 According to the often-cited Tufts 
Center for the Study of Drug Development, U.S. pharmaceutical companies 
spend upwards of four billion dollars on research and development on a 
single drug.117 GlaxoSmithKline, a major U.S. pharmaceutical company, 
spent $81,708 million on research and development from 1997 to 2011, and 
costs have only increased in recent years.118 These expenses accumulate 
through clinical trials and filing patents, but more often, through drug 
failure—fewer than one-in-ten medicines that enter Phase 1 testing make it 
into the market.119 These costs are often factored into the costs of drugs that 
actually enter the market, at least in the United States where pharmaceutical 
companies are able to price in research and development in a free market 
system.120 
The main issue concerning price reform via government price 
regulation in the United States is whether reforms would have a negative 
 
 113  Tironi, supra note 16. 
 114  See Salomeh Keyhani et al., US Pharmaceutical Innovation in an International Context, 100 AM. 
J. PUB. HEALTH 1075 (2010). 
 115  Knocke, supra note 80, at 181. 
 116  PHARMACEUTICAL RES. AND MFR. OF AM. (PHRMA), 2013 BIOPHARMACEUTICAL RESEARCH 
INDUSTRY PROFILE (2013), available at http://phrma.org/sites/default/files/pdf/PhRMA% 
20Profile%202013.pdf. 
 117  Matthew Herper, The Truly Staggering Cost of Developing New Drugs, FORBES (Feb. 10, 2012, 
7:41 AM), http://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-
inventing-new-drugs/. 
 118  Id. 
 119  Id. 
 120  Id. 
5SALTER.DOCX (DO NOT DELETE)  9/29/15 1:56 PM 
Reference Pricing and the United States 
35:413 (2015) 
433 
impact on pharmaceutical innovation. Most companies within the 
pharmaceutical industry, as well as many outside of it, argue that price 
reform would dampen innovation.121 The U.S. pharmaceutical market is a 
major source of profits for pharmaceutical companies, which allows these 
companies to cover losses in other countries. They may not be able to 
swallow the costs if the U.S. institutes price controls similar to other 
developed nations. 
The United States is home to an astoundingly large proportion of 
pharmaceutical research and development. Six of the ten largest drug 
companies are based in the United States.122 This is perhaps because 
pharmaceutical companies are allowed to set prices that let them recoup 
research and development costs.123 Many argue that price setting in the 
United States, especially under a system of reference pricing intended to 
equalize prices between nations, would lead to a decrease in research and 
development.124 This decrease would prevent potentially life-saving 
medications from eventually reaching not only the United States, but also 
the global market.125 The U.S. government has pressured other countries to 
limit their price regulation, arguing that price regulations cause the United 
States to bear a disproportionate amount of research and development 
expenses in order to support “free-rider” countries.126 The U.S. government 
has gone so far as to limit price negotiation in the 2003 Medicare 
Modernization Act.127 Meanwhile, the pharmaceutical industry has similar 
objections. The Pharmaceutical Manufacturers Association of America has 
strongly opposed regulation and claimed that foreign governments are 
benefitting from U.S. innovation rather than paying their fair share of 
development costs.128 
However, others argue that price setting in the United States would 
have a marginal (if any) effect on research and development overall.129 A 
 
 121  Christopher R. Stambaugh, State Price Control Laws Are the Wrong Prescription for the 
Problem of Unaffordable Drugs, 12 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 897, 900 (2002). 
 122  Trade, Foreign Policy, Diplomacy, and Health: Pharmaceutical Industry, WORLD HEALTH ORG., 
http://www.who.int/trade/glossary/story073/en/ (last visited Nov. 17, 2014). 
 123  See U.S. DEP’T. OF COMMERCE, INT’L TRADE ADMIN., PHARMACEUTICAL PRICE CONTROLS IN 
OECD COUNTRIES: IMPLICATIONS FOR U.S. CONSUMERS, PRICING, RESEARCH AND DEVELOPMENT, 
AND INNOVATION (2004) (discussing how government controlled pricing reduces development in 
contrast to the United States. “As OECD countries individually seek to reduce spending on drugs 
through price controls, their collective actions reduce R&D that would provide substantial health 
benefits to all.”), available at http://www.ita.doc.gov/td/chemicals/drugpricingstudy.pdf. Contra 
Keyhani, supra note 114. 
 124  Kraus, supra note 4; Stanton, supra note 1; Shah, supra note 79. 
 125  Stambaugh, supra note 121. 
 126  Keyhani, supra note 114, at 1075; Danzon, supra note 15. 
 127  Keyhani, supra note 114, at 1075. 
 128  Id. at 1075. 
 129  Id. at 1077–78. 
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2010 study found the following: 
 
[The] United States is important but not disproportionate in its 
contribution to pharmaceutical innovation. Interestingly, some 
countries with direct price control, profit control, or reference 
drug pricing appeared to innovate proportionally more than their 
contribution to the global GDP or prescription drug spending.130 
 
In other words, reference pricing is not directly correlated with a 
decrease in research and development. Others argue that while the United 
States may lead in pharmaceutical innovation, government and grant 
funding accounts for a large enough portion of this innovation to 
accommodate a decrease in private sector profits. Government funding has 
“played an indirect role—for example, by funding basic underlying research 
that is built on in the drug discovery process—in almost half of the drugs 
approved and in almost two-thirds of priority-review131 drugs.”132 
 
2. Balancing Profit Margins with Transformational Care 
 
Another issue that must be considered in applying reference pricing 
systems to the United States is balancing profit margins with the social goal 
of pharmaceutical innovation: transformational care. Transformational care 
is defined as “radical change introduced by visionary leaders at the level of 
the organization.” This can take on many forms, but often includes 
openness to new treatments and new medications, which are difficult to 
introduce under traditional management models which value continuity.133 
The profitability of the pharmaceutical industry allows pharmaceutical 
companies to devote money to large-scale innovation.134 These innovations 
include medicines that make large leaps in treatment and new therapies. 
Without the ability to recoup research and development costs, 
pharmaceutical companies may focus instead on cheaper incremental 
changes (this argument is similar to the argument often made that generic 
drugs limit innovation by discouraging originators, who see their profit 
 
 130  Id. at 1078. 
 131  Priority review drugs are drugs that, “if approved, would be significant improvements in the 
safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to 
standard applications.” When a drug is designated priority review, the FDA takes action on its approval 
within six months as opposed to the ten months expected under standard review. Priority Review, FDA 
(June 26, 2013), http://www.fda.gov/forpatients/approvals/fast/ucm405405.htm. 
 132  Bhaven N. Sampat & Frank R. Lichtenberg, What are the Respective Roles of the Public and 
Private Sectors in Pharmaceutical Innovation? 30 HEALTH AFFAIRS 332, 332 (2011). 
 133  Barbara Bigelow & Margaret Arndt, Transformational Change in Health Care: Changing the 
Question, 83 HOSPITAL TOPICS 19, 20 (2005). 
 134  Stanton, supra note 1. 
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margins shrinking).135 While important, these changes do not achieve the 
same level of transformational care that revolutionizes treatment. 
 
3. Grey and Black Market Pharmaceuticals 
 
One potential advantage to reference pricing in the United States is the 
decrease in parallel (grey) or black market imports.136 Parallel markets 
develop when “a product covered by intellectual property rights in country 
A is exported and resold to country B without the right holder’s 
authorization”; black markets involve the completely unregulated sale of 
drugs.137 Websites, like the now defunct Silk Road (perhaps more known 
for its supply of illegal drugs than cheaper but legal pharmaceuticals) and 
many other online havens, allow access to lower priced medications in 
regulated markets like Canada.138 Import of medications from Canada is a 
popular way to gain access to medicines that are prohibitively expensive in 
the United States.139 
Reference pricing in the United States may lead to lower prices that 
more closely equal those of Canada and other regulated nations.140 This 
may, in turn, lessen black or grey market importation. This theory, of 
course, supposes that reference groups in the United States and reference 
groups in countries like Canada, which are currently grey market importers, 
would be equivalent. If a drug is priced out of a reference group within the 
United States, black or grey market imports might continue or even 
increase. 
While grey-market imports allow customers to save on prescription 
drugs, they also come with risks for the consumer and the pharmaceutical 
market. Consumers take a risk when ordering prescription drugs through the 
internet or other grey market means of receiving incorrect or potentially 
dangerous pills. Additionally, grey markets allow consumers to self-
medicate without the expertise of a doctor to assure a correct diagnosis or a 
pharmacist to check dosages or interactions. Drugs without FDA approval 
are often obtainable through grey markets, and consumers may be unaware 
of damaging effects. Finally, like many Silk Road consumers who were 
located through their IP addresses during the government bust of the 
 
 135  See generally Beth Understahl, Authorized Generics: Careful Balance Undone, 16 FORDHAM 
INTELL. PROP. MEDIA & ENT. L.J. 355 (2005); Greger Vigen, Health Care 2.0—Massive Implications of 
System Transformation, HEALTH WATCH 10 (2013). 
 136  Grey markets, a play on the traditional term “black market” used to refer to illegal sale of goods, 
is generally used as a synonym for parallel markets. 
 137  Kraus, supra note 4, at 540. 
 138  Id. 
 139  Kraus, supra note 4. 
 140  Stanton, supra note 1. 
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website, consumers of grey market pharmaceuticals may face legal action. 
Even if no conviction results, the costs of such legal action certainly would 
exceed the cost of the legal prescription. 
Meanwhile, pharmaceutical developers suffer as well. Developers 
price their drugs for each country’s market. If sales at a lower price trickle 
into another country, these pricing models are no longer effective, and 
developers cannot properly estimate their returns on costs. 
 
C. Potential Effects on Patients and Providers 
 
Reference pricing, if instituted in the United States, could have a large 
effect on the healthcare industry at the patient and provider level. The 
current free-market pharmaceutical pricing in the United States has both 
positive and negative effects on providers. 
Pricing regulation may lead to pressure on physicians from 
pharmaceutical companies to prescribe their products through marketing.141 
In recent years, federal and state laws have restricted the use of marketing 
(and, through prosecution, attempted to discourage less open tactics like 
bribes) to persuade doctors to prescribe certain products. However, in the 
past, pharmaceutical companies have gone to extreme measures to get 
doctors to prescribe their products, from persuasive “perks” like trips and 
gifts to bribes.142 These extreme measures may not have been limited to a 
few untoward companies. In 2004, when federal prosecutors began to crack 
down on bribery and illegal marketing, “[j]ust about every big global drug 
company — including Johnson & Johnson, Wyeth and Bristol-Myers 
Squibb — ha[d] disclosed in securities filings that it ha[d] received a 
federal subpoena, and most [were] juggling subpoenas stemming from 
several investigations.”143 Many of these cases led to sanctions for 
pharmaceutical companies, or laws designed to lessen these abuses. In 
recent years, this marketing has become smaller in scale, controlled by 
federal gift limits and state marketing limitations.144 
Reference pricing might impact this smaller scale marketing, 
increasing it to levels that more closely mirror the actions the U.S. 
government attempted to cut down on in 2004. Pharmaceutical companies 
 
 141  Gardiner Harris, MEDICAL MARKETING — Treatment by Incentive; As Doctor Writes 
Prescription, Drug Company Writes a Check, N.Y. TIMES (June 27, 2004), 
http://www.nytimes.com/2004/06/27/us/medical-marketing-treatment-incentive-doctor-writes-
prescription-drug-company.html?pagewanted=all&src=pm. 
 142  See generally Novick v. Dep’t of Health, Bd. of Med., 816 So. 2d. 1237, 1238 (Fla. Dist. Ct. 
App. 2002). 
 143  Harris, supra note 141. 
 144  For examples of state regulations, see Marketing and Direct-to-Consumer Advertising of 
Pharmaceuticals, NAT’L CONF. OF STATE LEGISLATURES (last updated Oct. 2013), 
http://www.ncsl.org/research/health/marketing-and-advertising-of-pharmaceuticals.aspx. 
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express fear of reference pricing affecting profit margins: “recent 
developments threaten to wrest control of pricing, pharmaceutical 
companies’ single biggest determinant of profitability, further away from 
them.”145 With direct profits out of their hands, the pharmaceutical industry 
may react by pressuring doctors to endorse their products which fall outside 
the reference group and are not fully reimbursed by government or 
insurance payers, meaning patients would have to pay the difference out of 
pocket. 
 
D. Interaction with the Affordable Care Act 
 
The Affordable Care Act (ACA), a recent and highly contested piece 
of legislation passed by the Obama administration, attempts the difficult 
task of both reducing costs and increasing quality and accessibility of care 
within the United States. Many of these changes under the ACA will take 
place through changes in insurance coverage. Currently, the ACA does not 
address reference pricing as a cost saving mechanism for the healthcare 
industry. However, reference pricing might be an ideal way to achieve 
many of the goals of the ACA. 
One of the major goals of the ACA is to extend coverage to all 
citizens.146 Reference pricing would certainly make this goal more 
affordable for the government. Currently, one of the major criticisms of the 
ACA is the eventual cost of insuring the millions of uninsured through 
government-funded insurance. By balancing pharmaceutical costs and 
placing further regulations on what the government will pay for 
pharmaceuticals, reference pricing would lessen the gap between the federal 
budget and the cost of insuring every citizen under the ACA.147 
Reference pricing would certainly assist in increasing coverage, but 
whether the decrease in costs would be sufficient to achieve the ACA’s 
tandem goal of reducing costs is uncertain. Likewise, as discussed above, 
the ACA’s final goal of improving care may be difficult to achieve as 




In a globalized world, it is somewhat surprising that a system like 
reference pricing, utilized in every other developed nation and so 
entrenched in foreign pharmaceutical markets, is not used in the United 
 
 145  Pharmaletter, supra note 48. 
 146  Goal 1: Strengthen Health Care, HHS.GOV, http://www.hhs.gov/secretary/about/goal1.html. 
 147  John Cogan et al., A Better Way to Reform Healthcare, WALL ST. J. (Feb. 24 2010, 7:02 PM), 
http://online.wsj.com/news/articles/SB10001424052748704804204575069133264585068. 
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States. Certainly, there are downsides to reference pricing, most notably the 
potential harm to global research and development that would occur. 
However, the positive factors are substantial, such as a decrease in prices 
for consumers and government spenders. Overall, it seems that reference 
pricing in the United States may have a small negative effect on global 
markets, but an overall positive effect on consumers and providers in the 
United States, which far outweighs those factors. 
 
